DEERFIELD -- Baxter International Inc. said Monday its Baxter BioPharma Solutions division will produce a COVID-19 vaccine candidate for distribution in the United Kingdom and European markets.
Baxter BioPharma Solutions is a premier contract manufacturing organization that specializes in injectable pharmaceuticals, including vaccines. It has entered into an agreement to make Novavax' COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M adjuvant.
"The quest to develop vaccines for COVID-19 has reinforced the opportunity for industry partners to work together and contribute their unique capabilities and expertise for the benefit of all," said Marie Keeley, vice president, Baxter BioPharma Solutions. "We welcome the opportunity to work with an innovative company like Novavax and look forward to helping bring their vaccine candidate to the market."
Baxter's manufacturing services for Novavax will take place at its state-of-the-art facility in Halle/Westfalen, Germany.